CI Global Health Sciences Corporate Class

Series A CAD
 

Fund overview

This fund invests primarily in equity and equity-related securities of companies around the world that specialize in the health care or medical industry.

Fund details

description of elementelement value
Inception date July 1996
CAD Total net assets ($CAD)
As at 2026-09-30
$248.7 million
NAVPS
As at 2026-10-26
$59.2665
MER (%)
As at 2026-03-31
2.34
Management fee (%) 1.90
Units outstanding
As at
-
Asset class Sector Equity
Currency CAD
Minimum investment $500 initial/$25 additional
Distribution frequency Quarterly
Last distribution $0.9027

Risk rating1

  • Low
  • Low to medium
  • Medium
  • Medium to high
  • High

FUND CODES

A ISC 201
DSC SO* 701
LL SO 1701
E 16005
EF 15005
F 224
I 886
O 18005
P 90024
*No new purchases directly into switch only funds.

Performance2 As at 2026-09-30

Growth of $10,000 (Since inception date)

growth of 10k graph

Calendar year performance

annual performance graph

average annual compound returns

YTD 1 Mo 3 Mo 6 Mo 1 Y 3 Y 5 Y 10 Y Inception*
7.74% 0.72% 4.21% 16.85% 20.21% 4.97% 2.52% 3.14% 7.41%
*Since inception date

Distribution history3

Payable date Total
2022-03-25 0.9027
2021-03-26 0.3135
2020-12-18 0.5081
2020-09-25 0.5058
2020-06-26 0.3780
Payable date Total
2020-03-20 0.9301
2019-12-13 0.5339
2019-09-27 0.5996
2019-06-21 0.5646
2019-03-22 0.9043

CI PREFERRED PRICING4

Investment amount Combined fee reduction
$100,000 - $500,000 0.03%
$500,000 - $1,000,000 0.06%
$1,000,000 - $2,500,000 0.12%
$2,500,000 - $5,000,000 0.20%
$5,000,000 and above 0.32%

Management team

First we'll display the Team Company and then the Team members
Matthew Strauss

CI Global Health Sciences Corporate Class

Series A CAD
 
Portfolio allocations5 As at 2026-09-30
Asset allocation (%)
  • US Equity 80.67
  • International Equity 17.29
  • Canadian Corporate Bonds 2.44
  • Other -0.01
  • Cash and Equivalents -0.39
Sector allocation (%)
  • Healthcare 93.79
  • Exchange Traded Fund 3.66
  • Fixed Income 2.44
  • Other 0.50
  • Cash and Cash Equivalent -0.39
Geographic allocation(%)
  • United States 80.16
  • Switzerland 7.07
  • United Kingdom 6.31
  • Netherlands 3.93
  • Canada 1.39
  • Europe 0.63
  • Other 0.50
  • Denmark 0.01
Top holdings7
Sector (%)
1. Eli Lilly and Co Drugs 9.50%
2. Johnson & Johnson Drugs 8.06%
3. AbbVie Inc Drugs 7.08%
4. Thermo Fisher Scientific Inc Healthcare Equipment 6.38%
5. AstraZeneca PLC Drugs 6.31%
6. UnitedHealth Group Inc Healthcare Services 6.20%
7. Abbott Laboratories Healthcare Equipment 5.18%
8. Stryker Corp Healthcare Equipment 4.90%
9. Merck & Co Inc Drugs 4.83%
10. Danaher Corp Healthcare Equipment 4.74%
11. DexCom Inc Healthcare Equipment 4.47%
12. argenx SE Drugs 3.93%
13. SPDR S&P Biotech ETF (XBI) Exchange Traded Fund 3.66%
14. Vertex Pharmaceuticals Inc Drugs 3.43%
15. Novartis AG Cl N Drugs 3.26%
Over 35,000 financial advisors have chosen CI Global Asset Management as a partner. We believe that Canadians have the best opportunity for investments success by using the services of a professional financial advisor. Learn more at ci.com.